AGC
PFE icon

Aspen Grove Capital’s Pfizer PFE Stock Holding History

Aspen Grove Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
63,351
+766
+1% +$20K 0.22% 55
2026
Q1 		$1.76M Hold
62,585
– – 0.34% 47
2025
Q4 		$1.56M Buy
62,585
+279
+0.4% +$7.04K 0.27% 49
2025
Q3 		$1.59M Buy
62,306
+919
+1% +$22.7K 0.27% 52
2025
Q2 		$1.49M Sell
61,387
-1,559
-2% -$36.4K 0.25% 56
2025
Q1 		$1.6M Buy
62,946
+736
+1% +$19.3K 0.31% 49
2024
Q4 		$1.65M Sell
62,210
-1,414
-2% -$38.4K 0.35% 45
2024
Q3 		$1.84M Sell
63,624
-76
-0.1% -$2.22K 0.41% 41
2024
Q2 		$1.78M Buy
63,700
+1,754
+3% +$48.3K 0.42% 41
2024
Q1 		$1.72M Sell
61,946
-24,941
-29% -$692K 0.49% 40
2023
Q4 		$2.57M Sell
86,887
-954
-1% -$28.8K 0.78% 26
2023
Q3 		$2.91M Sell
87,841
-25,961
-23% -$918K 1.08% 19
2023
Q2 		$4.17M Buy
113,802
+1,176
+1% +$45.8K 1.35% 16
2023
Q1 		$4.6M Sell
112,626
-516
-0.5% -$22.3K 2.01% 11
2022
Q4 		$5.8M Buy
+113,142
New +$5.42M 2.68% 9

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Aspen Grove Capital's PFE Position: Q2 2026 in Review

Aspen Grove Capital increased its Pfizer (PFE) stake by 1.2% in Q2 2026, buying an estimated $20K and bringing the position to 63,351 shares worth $1.53M. The position accounts for 0.22% of the portfolio, ranked #55.

Aspen Grove Capital first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.8M in Q4 2022. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Aspen Grove Capital held 63,351 shares of Pfizer worth $1.53M as of Q2 2026.
  • Aspen Grove Capital bought 766 Pfizer shares in Q2 2026, an estimated $20K.
  • Pfizer made up 0.22% of Aspen Grove Capital's portfolio in Q2 2026, its #55 holding.
  • Aspen Grove Capital first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • Aspen Grove Capital's Pfizer position peaked at $5.8M in Q4 2022.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Aspen Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.